U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. How Drugs are Developed and Approved
  5. Drug and Biologic Approval and IND Activity Reports
  6. NDA and BLA Approvals
  7. Accelerated Approval Program
  1. NDA and BLA Approvals

The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint.  A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.

Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug.  If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.

Infectious Disease Indications Accelerated Approvals

Non-malignant Hematological, Neurological, and Other Disorder Indications Accelerated Approvals

Cancer Accelerated Approvals


Sub-Topic Paragraphs

Resources


Subscribe to email updates about accelerated approvals and more

Information about new and updated accelerated approvals plus recent news related to drugs

Back to Top